Stefano Gulla

Biotech founder

[Kling Biotherapeutics @KlingBio_]

📢Exciting breakthrough in the fight against #SARSCoV2 variants!

Using immortalized B cell libraries + ex vivo evolution, we developed potent antibodies that neutralize key variants like EG.5.1, JN.1 & NB.1.8.1.

🧬 Read more here 👉 https://t.co/cJK037hSAh

#PandemicResponse

[Kling Biotherapeutics @KlingBio_]

⚡News Flash⚡

Our CSO @StefanoGulla joins #BaseToBase for a special #StandUpToCancer (@SU2C @SU2CUK) episode to discuss the future of #cancer therapeutics and innovations at #KlingBio.

#SU2C @deeptech

🎧Listen here 👉 https://t.co/OslHQYlT2Z

[Kling Biotherapeutics @KlingBio_]

🚨 Don’t miss our CSO, @Stefano Gullà, in the next episode of the @ChineseAntibody Society Webinar series!

🗓️ Presented in English on Zoom.

👉 Register now: https://t.co/DVEDKZ1Wso

#immunooncology #antibodytherapeutics #drugdevelopment #drugdiscovery

[Kling Biotherapeutics @KlingBio_]

Join Alessandra Villa, @KlingBio_’s Director of Platform Development at #AACR2025 in Chicago 💨🏙️on April 28 at 2PM CDT as she presents our first-in-class primary B-cell selection & evolution platform. Don’t miss it!

#AACR2025

[Kling Biotherapeutics @KlingBio_]

In a @DDWJournal exclusive, our CSO, @Stefano Gulla shared his insights with @MegThomasTweets on the 2025 outlook for therapeutic #antibodies

Read the full article here👉https://t.co/mDIDoa4uOw

#DrugDevelopment #DrugDiscovery #ImmunOncology

[Kling Biotherapeutics @KlingBio_]

Connect with #Kling at #ESMOTAT to learn more about our commercially validated primary B-Cell screening and immortalization platform.

@myESMO

[Kling Biotherapeutics @KlingBio_]

Our CSO, @StefanoGulla shared his insights on the latest advances in biopharma and what we can expect to see in 2025 in the latest instalment of Scrip Asks.

Read about advancements in the development of multifunctional therapeutic antibodies here: https://t.co/REJ1Vd6cio

[Kling Biotherapeutics @KlingBio_]

In recognition of #WorldCancerDay 🌍, our CSO, @StefanoGullaspoke spoke with @Labiotech.eu to discuss why he believes B cells will play a key role in producing novel antibodies that recognize cancerous tissue.

Read here 👉https://t.co/4WaakZsVyb

[Kling Biotherapeutics @KlingBio_]

Join us on #WorldCancerDay to raise awareness about people-centered #cancer care. At #Kling, we are advancing our robust pipeline of #oncology and infectious disease programs using our primary B-cell selection and evolution platform technologies, Kling-Select and Kling-Evolve.

[Kling Biotherapeutics @KlingBio_]

Our CSO, @StefanoGulla, shared insights with @MegThomasTweets for the first installment of @DDWJournal's 2025 Industry Predictions series. Read about Kling’s proprietary primary B-cell screening technologies Kling-Select and Kling-Evolve here 👉 https://t.co/PYo4oDXfsI

[Kling Biotherapeutics @KlingBio_]

🛫Are you heading to @jpmorgan's Healthcare Conference?

Connect with @KlingBio_ to discuss future strategic developments to advance our pipeline of therapeutic #antibodies targeting novel antigens discovered using our clinically validated B-cell screening platform technologies.

[Kling Biotherapeutics @KlingBio_]

Introducing TuLibs (tumor libraries) – the latest addition to our powerful primary B-cell screening platform technologies.

Take a closer look below 👀 at TuLibs 👇!

Reach out to @KlingBio_ for partnership and collaboration opportunities to develop novel therapeutics.

[Kling Biotherapeutics @KlingBio_]

Our CSO, @StefanoGulla delves into the crucial role that B-cells play in the fight against #cancer in the latest #optimumperspectives #podcast edition.

#Kling is well-positioned to discover new insights from tumor-infiltrating B-cells with its B-cell immortalization technology.

[Kling Biotherapeutics @KlingBio_]

In the latest publication for @DDW, our CSO @StefanoGulla, sheds light🔦on the crucial role of #Bcells in the fight against #cancer and explores their potential in developing novel cancer #immunotherapies.

Read the full article here👉 https://t.co/El4nrtYoxw

[Kling Biotherapeutics @KlingBio_]

Connect🤝with @StefanoGulla at the #WorldVaccineCongress Europe (#WVCEU) presented by @Terrapinn to learn more about @KlingBio_'s clinically validated primary B-cell immortalization and screening platform technologies.

[pharmaphorum @pharmaphorum]

#Mpox – formerly known as monkeypox – is rapidly spreading in several African countries, prompting the WHO to declare a #publichealthemergency - but new approaches in #antibody research technology could halt this and other #outbreaks.

https://t.co/NpUBFwxz5j

[Kling Biotherapeutics @KlingBio_]

Join our CSO, @StefanoGulla at the @festofbiologics in Basel🗻where he will be presenting on @KlingBio_’s advancements in novel #immunotherapies with its proprietary primary B-cell selection and evolution platform on 16 Oct at 15.20 CEST!

[Waggoner Lab @LabWaggoner]

NK cells can be reprogrammed by breast cancer cells to promote metastasis. Reprogramming can be blocked by targeting NK cell inhibitory receptors TIGIT or KLRG1 or inhibiting DNA methyltransferases. https://t.co/AWfJetb7w7

[A Good Magazine @AGoodMag]

Tumore al seno. Si può prevenire le metastasi con il risveglio delle cellule Nk.
A scoprirlo sono stati i ricercatori della Johns Hopkins University.
La strategia è a base di anticorpi anti-Tigit e anti-Klrg1 e di inibitori delle Dna metiltransferasi.

#13luglio